Posted in Flagyl on September 18, 2015

OXFORD, United Kingdom, Sept. 18, 2015 (GLOBE NEWSWIRE) — Summit (NASDAQ:SMMT) (AIM:SUMM), the mix with ~s discovery and development company advancing therapies according to Duchenne Muscular Dystrophy and C. difficile taint (‘CDI’), announces new preclinical data up~ the body SMT19969, a novel and selective spoken antibiotic for the treatment of CDI, order be presented at the 55th Interscience Conference in successi~ Antimicrobial Agents and Chemotherapy (‘ICAAC 2015’) actuality held in San Diego, USA from September 17-21, 2015.

The premises being presented are from preclinical in vitro studies that procure further evidence to support SMT19969’s outline as a potential treatment for CDI and potency to reduce the high rates of return currently associated with the disease. SMT19969 was shown to acquire high potency against 107 clinical isolates of C. difficile selected to maximise the dissimilarity of their resistance to common classes of antibiotics, and SMT19969 besides continues to display a low hindrance development profile.

“These new data farther illustrate the promise of SMT19969 of the same kind with a differentiated antibiotic to treat CDI and, through its selective antibiotic side view, potential to leave the healthy intestine microbiome unharmed, and so address the elucidation clinical issue of disease recurrence,” commented Glyn Edwards, Chief Executive Officer of Summit. “It is an exciting time in the development of SMT19969 since we look forward to reporting rise aloft-line data from our Phase 2 essay of concept trial during the fourth furnish of this year.”

The results elect be detailed in two poster presentations to be given by Summit’s collaborators: Professor Mark Wilcox (Leeds Teaching Hospitals and University of Leeds, UK) and Dr Joseph Blondeau (Royal University Hospital and the University of Saskatchewan, Canada). The minutiae of the presentations are as follows:

SMT19969 has advantage activity against prevalent Clostridium difficile ribotypes through varying antimicrobial resistance

J Freeman, J Vernon, R Vickers and M.H. Wilcox (Poster C-618)

This study assessed SMT19969 in preparation for 107 clinical isolates of C. difficile that had been selected to maximise the multitude of the isolates resistance to lock opener classes of commonly used antibiotics. The results confer that SMT19969 was highly active facing all C. difficile clinical isolates, displayed preferable potency against C. difficile isolates compared to vancomycin and metronidazole, and to be compared potency to fidaxomicin. SMT19969 displayed ~t one evidence of cross-resistance with other classes of antibiotics in ordinary way clinical use.

Mutant Prevention Concentration values of SMT19969 in anticipation of Clostridium difficile isolates using a modified microbroth dilution method

J.M. Blondeau, S Shebelski, R. Vickers (Poster D-212)

The study evaluated the mutant stoppage concentration (‘MPC’) of SMT19969 to fix upon the drug concentration threshold that blocks the increase of the least susceptible cells grant in bacterial populations. The results appear that SMT19969 had low MPC values for clinical isolates of C. difficile and procure further evidence supporting its low check development profile.

Copies of the presentations given at ICAAC 2015 be inclined be available from the ‘Programmes’ division of Summit’s website, from 20 September 2015.

The disentanglement of SMT19969 is being supported by a Wellcome Trust Translational Award.

Notes to Editors

About C. difficile Infection

C. difficile taint is a serious healthcare threat in hospitals, lingering-term care homes and increasingly the wider community. It is a serious illness caused ~ dint of. infection of the colon by the bacteria C. difficile, which produces toxins that cause inflammation, stinging diarrhoea and in the most dangerous cases can be fatal. Patients typically grow CDI following the use of extended-spectrum antibiotics that can cause widespread impair to the natural gastrointestinal (gut) flora and allow overgrowth of C. difficile bacteria. Existing CDI treatments are vulgar spectrum antibiotics and these cause farther damage to the gut flora and are associated by high rates of recurrent diseaseDisease resort is the key clinical issue viewed like repeat episodes are typically more sedate and associated with an increase in death rates and healthcare costs. The relating to housekeeping impact of CDI is significant with one study estimating annual acute care costs at $4.8 billion in the US.

(C) Copyright 2015 GlobeNewswire, Inc. All rights kept.

In the 1930’s the unemployment be~ had reached its peak and similar to a result thousands of businesses had both cut their workforce or had gone through of business during the depression.